EP0000742B1 - Corticoid-17-Alkylcarbonate und Verfahren zu deren Herstellung und diese enthaltende Mittel - Google Patents

Corticoid-17-Alkylcarbonate und Verfahren zu deren Herstellung und diese enthaltende Mittel Download PDF

Info

Publication number
EP0000742B1
EP0000742B1 EP78100524A EP78100524A EP0000742B1 EP 0000742 B1 EP0000742 B1 EP 0000742B1 EP 78100524 A EP78100524 A EP 78100524A EP 78100524 A EP78100524 A EP 78100524A EP 0000742 B1 EP0000742 B1 EP 0000742B1
Authority
EP
European Patent Office
Prior art keywords
carbonate
acid chloride
iso
methyl
chloroformate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP78100524A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0000742A1 (de
Inventor
Ulrich Dr. Stache
Werner Dr. Fritsch
Hans Georg Dr. Alpermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of EP0000742A1 publication Critical patent/EP0000742A1/de
Application granted granted Critical
Publication of EP0000742B1 publication Critical patent/EP0000742B1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0047—Nitrogen only at position 2(3)

Definitions

  • R 5 methyl, ethyl, propyl, phenyl and the other substituted phenyl radicals mentioned for R 5 , the substituents each being in the p-position.
  • a carboxylic acid such as, for example, ants, vinegars, propions, butter , Valerian, oxalic, maleic, fumaric, succinic or adipic acid, or an organic sulfonic acid, such as p-toluene, benzene, p- or o- or m-chloro- or bromobenzenesulfonic acid or one inorganic acid, such as hydrochloric, sulfuric, carbonic, nitric acid used.
  • a carboxylic acid such as, for example, ants, vinegars, propions, butter , Valerian, oxalic, maleic, fumaric, succinic or adipic acid, or an organic sulfonic acid, such as p-toluene, benzene, p- or o- or m-chloro- or bromobenzenesulfonic acid or one inorganic acid, such as hydrochloric, sulfuric, carbonic
  • water or / and inert organic solvents such as alcohols, linear or cyclic ethers, esters, dialkylformamides, dialkylsulfoxides or hexamethylphosphoric acid triamide, for dilution, often in addition to the dilution effect a catalytic or regioselective effect in the direction of the desired course of the reaction is brought about.
  • the course of the reaction in the desired direction is expediently followed by thin-layer chromatography. It is advantageous to terminate the reaction by neutralizing, for example, with dilute ammonia or adjusting the pH to above 7, if the thin-layer diagram, after optimal formation of the desired steroid-17 '-monoalkylcarbonate-21-hydroxy compounds, isometrized to the undesired steroid- Indicate 17-hydroxy-21-monoalkyl carbonate compounds.
  • the corticoid-17,21-orthoalkyl carbonate is preferably dissolved in a carboxylic acid, such as, for example, in acetic acid or propionic acid, preferably about 0.1 to 1% water is added and the mixture is left for up to about 8 hours at a temperature of 0 ° to react to the boiling point of the acid or solvent used.
  • a carboxylic acid such as, for example, in acetic acid or propionic acid
  • the reaction mixture is stirred into water or saline, neutralized, for example, with aqueous ammonia or another weak base, either the precipitate is suctioned off or extracted in a conventional manner with organic solvents, evaporates, recrystallizes the products obtained and chromatographs them, if the starting material or 21-alkyl carbonate is still detectable in the TLC diagram, if necessary on silica gel or aluminum oxide.
  • the steroid component is dissolved in an inert solvent, such as, for example, in an ether, such as dioxane, tetrahydrofuran, diglyme, or optionally halogenated hydrocarbon, such as benzene, toluene, cyclohexane, methylene chloride, chloroform or in a mixture of these solvents.
  • an ether such as dioxane, tetrahydrofuran, diglyme
  • optionally halogenated hydrocarbon such as benzene, toluene, cyclohexane, methylene chloride, chloroform or in a mixture of these solvents.
  • 1-1000 molar equivalents of a tertiary base such as pyridine, quinoline, triethylamine or dimethylaniline are added. You can also use an organic base such as sodium bicarbonate or calcium carbonate to remove the acid.
  • 1-200 molar equivalents, preferably 1-3 molar equivalents, of one of the above-mentioned acylating agents, optionally dissolved in one of the above-mentioned solvents, are added dropwise at a temperature between -40 ° C. and the boiling point of the solvent used, preferably between 0 ° C. and 25 ° C, too.
  • the reaction mixture is then left to stand for from one to 120 hours at a temperature between -40 ° C. and the boiling point of the solvent, preferably between 0 ° C. and 25 ° C.
  • reaction mixture For working up, the reaction mixture is poured into water, to which sodium bicarbonate has optionally been added, the reaction products generally precipitating out in crystalline form, often only after prolonged standing. Reaction products that have remained oily are enriched by shaking with a suitable extractant and evaporation. If necessary, the reaction products can be separated or purified by recrystallization or by chromatography. Intensive digestion in an organic solvent which dissolves the reaction product as little or as little as possible, such as diethyl ether or cyclohexane or a mixture of these components, is often sufficient for further purification of the reaction products.
  • an organic solvent which dissolves the reaction product as little or as little as possible, such as diethyl ether or cyclohexane or a mixture of these components, is often sufficient for further purification of the reaction products.
  • a hydroxy group in the 11-position can optionally be oxidized to the keto group by customary methods. This oxidation is preferably carried out with chromium trioxide in an acidic medium and in an inert organic solvent.
  • the process products have valuable pharmacological properties. They have a particularly strong local and topical anti-inflammatory activity and in some cases show an advantageous ratio of local to systemic anti-inflammatory activity, as can be derived from standard pharmacological tests.
  • the invention also relates to an agent for the treatment of inflammatory dermatoses consisting of or comprising a compound of the formula or II.
  • the process products can be used in veterinary and human therapy for the treatment of inflammatory dermatoses of various origins in the form of suspensions, ointments, creams, sprays, etc. When applied topically, they can be applied in the form of crystal suspensions - for example, during intra-articular injection. It should be emphasized as particularly advantageous for the local and topical form of therapy that the process products, due to their favorable ratio of local to systemic antiphlogistic effect, are also long-term in the case of high doses therapy can practically only cause minor systemic side effects. In addition, the process products used have a significantly better acid stability than the cyclic corticoid-17,21-ortho-carbonates on which they are based. This fact is of crucial importance for a safe and therapy-rich registration of the products according to the invention.
  • ointments, creams, suspensions, etc. with a concentration of 0.01 to 2% by weight are used, for topical administrations in the form of local (non-systemic) injections, doses of 0.1 mg to 100 mg .
  • the IR spectra (in KBr) are recorded with the Perkin-Elmer 521 grating spectrophotometer. Only the characteristic bands are listed.
  • the UV spectra (in methanol) were recorded with the Beckman DK 1 A spectrophotometer.
  • the mass spectrometric investigations (MS) are carried out with the MS 9 device (from AEI).
  • the dexamethasone 17-ethyl carbonate-21-butyrate of mp 202-205 ° C. is obtained.
  • the 4.45 g of 6 ⁇ -fluoro-prednisolone-17 ⁇ -ethyl carbonate obtained with a melting point of 133 ° -136 ° can thus be reacted immediately without further purification as follows.
  • the above substance is dissolved in 60 ml of absolute pyridine and, after cooling to 0 °, 2.3 ml of propionic acid chloride are added. After 1 hour at 0 ° and a further hour at 20 °, the reaction mixture is stirred into 500 ml of semi-saturated aqueous sodium chloride solution. The mixture is then extracted with methylene chloride, the organic phase is washed neutral with water, dilute hydrochloric acid and water, dried and evaporated to dryness in vacuo.
  • the 4.95 g of crude 6 ⁇ -fluoro-prednisolone-17 ⁇ -ethyl carbonate-21-propionate obtained can be purified as follows.
  • Example 2a chromatography is carried out on a column of 250 g of silica gel and worked up. At the end, the product is recrystallized from ether / petroleum ether and 2.55 g of 6 ⁇ -fluoro-prednisolone-17a-ethyl carbonate-21-propionate, mp.
  • the 6 ⁇ -fluoro-prednisolone-17 ⁇ , 21-diethyl orthocarbonate used as starting material is obtained analogously according to DBP 16 68 079 as follows.
  • a solution of 4.75 g of 6 ⁇ -fluoro-prednisolone in 180 ml of anhydrous dioxane is stirred for 15 hours at room temperature after the addition of 13 ml of tetraethyl orthocarbonate and 0 29 g of p-toluenesulfonic acid. Then the reaction mixture is poured into a solution of 1.5 g of sodium hydrogen carbonate in 950 ml of water. The precipitated crystals are collected, washed with water, dried and recrystallized from acetone.
  • reaction mixture is poured into a solution of 6.0 g of sodium hydrogen carbonate in 4.0 l of water.
  • the mixture is then worked up as described in Example 7. 21.1 g of 6a-methyl-prednisolone-17 ⁇ , 21-bis - (ethyl carbonate) of mp 109-112 were obtained.
  • prednisolone dimethyl orthocarbonate (R F -0.6) initially required for the reaction is prepared from prednisolone and tetra-methyl orthocarbonate according to DBP 1 668 079.
  • cortisone dimethyl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared from cortisone and tetramethyl orthocarbonate according to DBP 1 668 079.
  • cortisol dimethyl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is produced from cortisol and tetramethyl orthocarbonate according to DBP 1 668 079.
  • betamethasone 17-methyl carbonate-21-p-toluenesulfonate or -21-p-chlorobenzenesulfonate is obtained.
  • the betamethasone dimethyl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared from betamethasone and tetra methyl orthocarbonate in accordance with DBP 1 668 079.
  • the former is then hydrolyzed to 6a, 16a or ⁇ -dimethyl-prednisolone-17-methyl carbonate (R F ⁇ 0.4) in the same manner as described in Example 1 c).
  • prednisolone diethyl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared from prednisolone and tetraethyl orthocarbonate in accordance with DBP 1 668 079.
  • prednisone diethyl orthocarbonate (R F -0.6) initially required for the reaction is prepared from prednisone and tetraethyl orthocarbonate according to DBP 1 668 079.
  • cortisone diethyl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared from cortisone and tetraethyl orthocarbonate according to DBP 1 668 079.
  • cortisol diethyl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared according to DBP 1 668 079 from cortisol and tetraethyl orthocarbonate.
  • the betamethasone diethyl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared from betamethasone and tetraethyl orthocarbonate according to DBP 1 668 079.
  • the former is then hydrolyzed to 6a, 16 ⁇ - or ⁇ -dimethyl-prednisolone-17-ethyl carbonate (R f - 0.4) in the same manner as described in Example 1 c).
  • prednisolone di-n-propyl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared from prednisolone and tetra-n-propyl orthocarbonate according to DBP 1 668 079.
  • prednisone di-n-propyl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared from prednisone and tetra-n-propyl orthocarbonate according to DBP 1 668 079.
  • cortisone di-n-propyl orthocarbonate (R F - 0.6) initially required for the reaction is prepared from cortisone and tetra-n-propyl orthocarbonate in accordance with DBP 1 668 079.
  • cortisol di-n-propyl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared from cortisol and tetra-n-propyl orthocarbonate according to DBP 1 668 079.
  • the betamethasone di-n-propyl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared according to DBP 1 668079 from betamethasone and tetra-n-propyl orthocarbonate.
  • Example 2 f In the same manner as described in Example 2 f), 3 g of 6 ⁇ , 16 ⁇ - or ⁇ -dimethyl-prednisolone-17-n-propyl carbonate are reacted with methanesulfonic acid chloride and worked up. After crystallization from ether, 6a, 16a or ß-dimethyl-prednisolone-17-n-propyl carbonate-21-methanesulfonate is obtained.
  • the first is then hydrolyzed to 6 ⁇ , 16 ⁇ - or ⁇ -dimethyl-prednisolone-17-n-propyl-carbonate (R F ⁇ 0.4) in the same manner as described in Example 1 c).
  • prednisolone divaleryl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared from prednisolone and tetravaleryl orthocarbonate according to DBP 1 6680 9. The former is then hydrolyzed to prednisolone-1 7-valeryl carbonate (R F ⁇ 0.4) in the same manner as described in Example 1 c).
  • prednisone di-valeryl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared from prednisone and tetra-valeryl orthocarbonate in accordance with DBP 1 668 079. Then will the former hydrolysed to prednisone-1 7-valeryl carbonate (R F ⁇ 0.4) in the same way as described in Example 1 c).
  • cortisone di-valeryl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is produced from cortisone and tetra-valeryl orthocarbonate in accordance with DBP 1 668 079. The former is then hydrolyzed to cortisone 17-valeryl carbonate (R F -0.4) in the same manner as described in Example 1 c).
  • cortisol di-valeryl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared from cortisol and tetra-valeryl orthocarbonate in accordance with DBP 1 668 079. The former is then hydrolyzed to cortisol-17-valeryl carbonate (R F ⁇ 0.4) in the same manner as described in Example 1 c).
  • betamethasone di-valeryl orthocarbonate (R F ⁇ 0.6) initially required for the reaction is prepared from betamethasone and tetravaleryl orthocarbonate in accordance with DBP 1 668 079. The former is then hydrolyzed to betamethasone-17-valeryl carbonate (R F ⁇ 0.4) in the same manner as described in Example 1 c).
  • bimedrazole-17-n-propyl carbonate (representation: bimedrazole + tetra-n-propyl orthocarbonate instead of tetraethyl orthocarbonate initially gives the amorphous bimedrazole - 17.21 - di - n - propyl orthocarbonate, which is then analogous is selectively solvolysed in glacial acetic acid / water), the corresponding -21-carboxylic acid esters, -21-carbonates and -21-sulfonic acid esters are shown.
  • the cortisol, cortisone, prednisolone, prednisone, 6 ⁇ -methylprednisolone, 6 ⁇ -fluoro-prednisolone, betamethasone beclomethasone, 9 ⁇ -chloro, 16 ⁇ -methyl-prednisolone, 9 ⁇ - Fluorine - dexamethasone - 17 - ethyl carbonate used in the reaction, the corresponding 21-chloroacetates of the above-mentioned corticoid 17-ethyl carbonates are obtained after analogous reaction and working up.
  • the homologous corticoid-17-n-propyl-ocarbonates are used in the reaction, the corresponding corticoid-17-n-propyl carbonate-21-chloroacetate is obtained after analogous reaction control and processing .
  • the foam obtained is recrystallized from acetone / diisopropyl ether and gives 2.1 g of 11-dehydrodexamethasone - 17.21 bis - [ethyl carbonate] of mp 212 ° C.
  • the corticoid 17-alkyl carbonates dargestellen in the preceded examples in the 11-position and a hydroxyl group in 21 - Position either an alkyl carbonate or alkyl carboxylic acid ester or alkyl or arylsulfonic acid ester group, used in the oxidation reaction just described, the corresponding 11-dehydro-corticoid-17-alkyl carbonate-21-alkyl carbonates or 21-alkyl carboxylic acid esters, or -21-alkyl sulfonic acid esters, or -21-aryl sulfonic acid esters.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
EP78100524A 1977-08-04 1978-07-27 Corticoid-17-Alkylcarbonate und Verfahren zu deren Herstellung und diese enthaltende Mittel Expired EP0000742B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2735110 1977-08-04
DE19772735110 DE2735110A1 (de) 1977-08-04 1977-08-04 Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
EP0000742A1 EP0000742A1 (de) 1979-02-21
EP0000742B1 true EP0000742B1 (de) 1982-05-12

Family

ID=6015590

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78100524A Expired EP0000742B1 (de) 1977-08-04 1978-07-27 Corticoid-17-Alkylcarbonate und Verfahren zu deren Herstellung und diese enthaltende Mittel

Country Status (13)

Country Link
US (1) US4242334A (enrdf_load_stackoverflow)
EP (1) EP0000742B1 (enrdf_load_stackoverflow)
JP (1) JPS5436248A (enrdf_load_stackoverflow)
AT (1) AT372093B (enrdf_load_stackoverflow)
AU (1) AU522854B2 (enrdf_load_stackoverflow)
CA (1) CA1118411A (enrdf_load_stackoverflow)
DE (2) DE2735110A1 (enrdf_load_stackoverflow)
DK (1) DK154145C (enrdf_load_stackoverflow)
EG (1) EG13560A (enrdf_load_stackoverflow)
ES (1) ES472147A1 (enrdf_load_stackoverflow)
HU (1) HU182732B (enrdf_load_stackoverflow)
IT (1) IT1097652B (enrdf_load_stackoverflow)
ZA (1) ZA784417B (enrdf_load_stackoverflow)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2817988A1 (de) * 1978-04-25 1979-11-08 Hoechst Ag Corticoid 17-alkylcarbonate und verfahren zu deren herstellung
SE449106B (sv) * 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
US4996335A (en) * 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4456602A (en) * 1982-08-23 1984-06-26 The Upjohn Company Amine containing ester prodrugs of corticosteroids
US4443440A (en) * 1982-08-30 1984-04-17 The Upjohn Company Amine containing ester prodrugs of corticosteroids
AU558725B2 (en) * 1983-09-07 1987-02-05 Mitsubishi Kasei Corporation Corticoid derivatives
JPS6056997A (ja) * 1983-09-07 1985-04-02 Mitsubishi Chem Ind Ltd 新規な６−酸素化コルチコイド／７α−カ−ボネ−ト誘導体およびその製法
AU572589B2 (en) 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
PT78973A (en) * 1984-07-25 1984-08-01 Joao Emerico Villax New preparation process of the 9alpha-fluoro 17,21-acylates or hidroxilades in 17 and 21 chloro-corticosteroid
DE3637806A1 (de) * 1986-11-06 1988-05-19 Hoechst Ag Verfahren zur herstellung von prednisolon-17-ethylcarbonat durch umlagerung von prednisolon-21-ethylcarbonat
DE4025342A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
DE4328819A1 (de) * 1993-08-27 1995-03-02 Hoechst Ag Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE4333920A1 (de) * 1993-10-05 1995-04-13 Hoechst Ag Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
RU2171810C2 (ru) * 1999-07-21 2001-08-10 Научно-исследовательский институт наркологии 17α-АЦЕТАТ-21-ПИВАЛОАТ 17α, 21-ДИГИДРОКСИПРЕГН-4-ЕН-3,20-ДИОН, ОБЛАДАЮЩИЙ АНТИАЛКОГОЛЬНОЙ И АНКСИОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ
US20060229258A1 (en) * 2003-07-30 2006-10-12 Daniela Serikaku Steroidal compositions containing hydroxycarboxylic acids and methods of using the same
RU2387646C2 (ru) * 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
BRPI0617674A2 (pt) 2005-10-19 2011-08-02 Ranbaxy Lab Ltd composições farmacêuticas e seus usos
US20090054382A1 (en) * 2005-10-19 2009-02-26 Abhijit Ray Compositions of phosphodiesterase type iv inhibitors
MX2009003100A (es) * 2006-09-22 2009-05-11 Ranbaxy Lab Ltd Inhibidores de fosfodiesterasa tipo iv.
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CN101200484B (zh) * 2006-12-13 2010-12-08 天津天药药业股份有限公司 一种甾体开环物的生产工艺方法
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
US8420666B2 (en) * 2007-03-14 2013-04-16 Ranbaxy Laboratories Limited Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors
WO2009044200A1 (en) * 2007-10-04 2009-04-09 Astrazeneca Ab Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity
KR20100102121A (ko) * 2007-12-20 2010-09-20 아스트라제네카 아베 글루코코르티코스테로이드 수용체 효능제로서 작용하는 스테로이드 유도체
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
UY32525A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
UY32521A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Combinación para emplear en el tratamiento de enfermedades respiratorias
UY32523A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
UY32520A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
UA116622C2 (uk) 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей
CN102964414A (zh) * 2012-12-14 2013-03-13 中国科学院上海有机化学研究所 17位甾体羧酸酯的合成方法
CN110684068A (zh) * 2018-07-04 2020-01-14 成都文帆生物医药研发有限公司 一种制备泼尼卡松中间体的方法
CN116023425B (zh) * 2023-03-28 2023-06-20 南京师范大学 曲安西龙衍生物及其医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH429716A (de) * 1961-06-24 1967-02-15 Vismara Francesco Spa Verfahren zur Herstellung von 17a-Acyloxy-21-hydroxy-Steroiden
US3422193A (en) * 1966-08-11 1969-01-14 Schering Corp 17-mono esters of corticoids
DE1668079B2 (de) * 1968-01-18 1976-09-16 Hoechst Ag, 6000 Frankfurt Dialkylorthocarbonate von 17alpha, 21-dihydroxysteroiden und verfahren zu ihrer herstellung
US3558675A (en) * 1969-06-30 1971-01-26 Merck & Co Inc Steroid carbonates and process
GB1440063A (en) * 1972-08-11 1976-06-23 Glaxo Lab Ltd 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids

Also Published As

Publication number Publication date
CA1118411A (en) 1982-02-16
EP0000742A1 (de) 1979-02-21
IT7826424A0 (it) 1978-08-02
DE2861809D1 (en) 1982-07-01
EG13560A (en) 1981-12-31
DE2735110A1 (de) 1979-02-15
JPH0112758B2 (enrdf_load_stackoverflow) 1989-03-02
DK154145B (da) 1988-10-17
DK344978A (da) 1979-02-05
ZA784417B (en) 1979-08-29
ES472147A1 (es) 1979-03-16
DK154145C (da) 1989-02-27
AU522854B2 (en) 1982-07-01
ATA564578A (de) 1983-01-15
IT1097652B (it) 1985-08-31
AT372093B (de) 1983-08-25
AU3861178A (en) 1980-02-07
JPS5436248A (en) 1979-03-16
HU182732B (en) 1984-03-28
US4242334A (en) 1980-12-30

Similar Documents

Publication Publication Date Title
EP0000742B1 (de) Corticoid-17-Alkylcarbonate und Verfahren zu deren Herstellung und diese enthaltende Mittel
EP0004975B1 (de) Corticoid-17-Alkylcarbonate, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel gegen Dermatosen
EP0640616B1 (de) Corticosteroid-17-alkylcarbonat-21-(O)-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2649753A1 (de) Verfahren zur herstellung von steroiden
EP0470617A2 (de) In 17-Stellung substituierte Corticoid-17-alkylcarbonate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
CH629825A5 (de) Verfahren zur herstellung von terpenoiden estern von steroiden der pregnanreihe.
DE2755547C2 (enrdf_load_stackoverflow)
CH505802A (de) Verfahren zur Herstellung von Estern von 17a-Hydroxysteroiden der Pregnanreihe
DE2538595A1 (de) Steroidverbindungen
CH645388A5 (de) Verfahren zur acylierung von tertiaeren sterisch gehinderten hydroxylgruppen von steroiden.
DE1768345B2 (de) Dimere steroid-21-alkylcarbonate und verfahren zu ihrer herstellung
CH641476A5 (de) Hydrocortison-17,21-diester und verfahren zu deren herstellung.
EP0077541B1 (de) Delta-1,3,5-3-Chlor-11-Beta,16-Alpha,17-Alpha,21-tetra-(hydroxy)-pregnan-20-on-16,17-acetonidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE1668079B2 (de) Dialkylorthocarbonate von 17alpha, 21-dihydroxysteroiden und verfahren zu ihrer herstellung
CH655320A5 (de) Verfahren zur herstellung von corticosteroid-estern mittels selektiver solvolyse.
EP0708111B1 (de) 17-Desoxi-corticosteroid-21-[O]-Carbonsäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2365992A1 (de) 6 alpha-fluor-17,21-dihydroxy-16 beta-methylpregna-4,9(11)-dien-3,20- dion-17,21-diacetat und verfahren zu dessen herstellung
DE69215932T2 (de) Ester von Pregna-21-säure
DD232497A5 (de) Verfahren zur herstellung von neuen corticoidderivaten
DE2644556C3 (de) Verfahren zur Herstellung von 17 a-Monoestern von 17 a, 21- Dihydroxysteroiden
DE1518915C (de) 17 alpha Alkanoyloxy 9 alpha fluor 11 oxy bzw 11 beta hydroxy 16 beta methyl pregna 1,4 dien 3,20 dione und Verfahren zu deren Herstellung
AT253135B (de) Verfahren zur Herstellung neuer Steroidverbindungen
DE1793630C3 (de) 17 alpha-Alkanoyloxy-9 alpha-fluor-11 beta-hydroxy-16-methyl-pregna-1 ,4dien-3,20-dione und Verfahren zu deren Herstellung
EP0011121A1 (de) Hydrocortisonester, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung
AT364098B (de) Verfahren zur herstellung von neuen estern von androstadien-17-carbonsaeuren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE FR GB NL SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE FR GB NL SE

REF Corresponds to:

Ref document number: 2861809

Country of ref document: DE

Date of ref document: 19820701

EAL Se: european patent in force in sweden

Ref document number: 78100524.4

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCF

Free format text: CHSPCFIKS 49676,49677,49678,49679/900720, 960223

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCG

Free format text: IKS 49676,49677,49678,49679/19900720, 19960223, EXPIRES:20030726

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19970619

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19970630

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19970702

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19970723

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19970808

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19970822

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19970922

Year of fee payment: 20

BE20 Be: patent expired

Free format text: 980727 *HOECHST A.G.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980726

Ref country code: CH

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980728

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Effective date: 19980726

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 19980727

EUG Se: european patent has lapsed

Ref document number: 78100524.4

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCM

Free format text: HOECHST AKTIENGESELLSCHAFT 65926 FRANKFURT AM MAIN (DE)TRANSFER-AVENTIS PHARMA DEUTSCHLAND GMBH 65926 FRANKFURT AM MAIN (DE)

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT